Diabetes, hypertension, and older age are associated with lower hospital readmission in patients with gastroparesis, while higher length of stay (LOS), drug abuse, and marijuana use increase the 30-day readmission rate, a study has shown.
Administering extended doses of mirikizumab for an additional 12 weeks successfully produces a clinical response in up to 50 percent of ulcerative colitis (UC) patients who did not benefit from 12 weeks of induction doses, according to the results of a phase II trial.
Treatment with infliximab to control inflammation effectively reduces parameters that are associated with a higher risk of venous thromboembolism in patients with inflammatory bowel disease (IBD), results of a study have shown.
In the treatment of patients with inflammatory bowel disease (IBD), comorbidities, but not patient age, influence the risk of any infection or hospitalizations on either vedolizumab or ustekinumab, a study suggests.
Patients with inflammatory bowel diseases (IBDs) suffer from higher mortality rates and are at an increased risk of cancer when they develop new-onset primary sclerosing cholangitis, a recent study has found.
The associations of anxiety, depression, and chronic inflammation with aortic pulse wave velocity (aPWV) and systolic blood pressure (SBP) indicate the first evidence of a brain–gut–vascular axis and new potential targets for treatment in patients with Crohn’s disease (CD), reveals a study.
Use of nonvitamin K antagonist oral anticoagulants (NOACs), particularly dabigatran, is associated with a significantly reduced risk of laboratory-based liver injury among patients with atrial fibrillation (AF) when compared with warfarin, results of a recent study have shown.
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.